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hsa-miR-31-5p G12 cel-miR-39-3p H01 Figure S2 . Expression analysis of miR-125b-5p, miR-143-3p and miR-145-5p by using the The Cancer Genome Atlas database (TCGA). Expression levels of the indicated miRNAs in breast tissue samples (normal = 104, and tumor = 1076) (A), trend of miRNAs profile with staging of the disease (B), and among them (C).
